HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in HENRY JI - SORRENTO THERAPEUTICS 25+ years of experience in the biotechnology and life sciences industry Dr. Ji co-founded Sorrento and has served as a director since 2006, CEO and President since 2012, and Chairman since 2017 During his tenure at Sorrento, he has engineered and led a phenomenal growth of Sorrento through acquisition and merger including Bioserv, Scilex

Pharmaceuticals,

NAJJAM ASGHAR

Najjam Asghar. Mr. Asghar serves as Chief Financial Officer (CFO) leading the functions of Finance, Accounting and Tax and has over 17 years of experience. Prior to his appointment as the Company’s CFO, Mr. Asghar served as Chief Accounting Officer since June 2019. Prior to joining Sorrento, he worked at NuVasive, Inc. leading various EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in HENRY JI - SORRENTO THERAPEUTICS 25+ years of experience in the biotechnology and life sciences industry Dr. Ji co-founded Sorrento and has served as a director since 2006, CEO and President since 2012, and Chairman since 2017 During his tenure at Sorrento, he has engineered and led a phenomenal growth of Sorrento through acquisition and merger including Bioserv, Scilex

Pharmaceuticals,

NAJJAM ASGHAR

Najjam Asghar. Mr. Asghar serves as Chief Financial Officer (CFO) leading the functions of Finance, Accounting and Tax and has over 17 years of experience. Prior to his appointment as the Company’s CFO, Mr. Asghar served as Chief Accounting Officer since June 2019. Prior to joining Sorrento, he worked at NuVasive, Inc. leading various EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

SMARTPHARM THERAPEUTICS, INC SmartPharm Therapeutics, Inc. (“SmartPharm”), a wholly owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), is a development stage biopharmaceutical company focused on next-generation, non-viral gene therapies for the treatment of serious or rare diseases with the vision of creating “biologics from within.” SmartPharm is currently developing a novel, DNA-encoded

monoclonal

COVIDROPS - SORRENTO THERAPEUTICS COVIDROPS™ (Intranasal COVI-AMG Neutralizing Antibody – STI 2099) In addition to the intravenous formulation of COVI-AMG™ neutralizing antibody, Sorrento is developing COVIDROPS which will be the intranasal formulation of COVI-AMG™. A few highlights of the preclinical animal data from the most recent STI-2099 study include: Intravenously-dosed animals recovered from the infection with PIPELINE - SORRENTO THERAPEUTICS Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval COVID-19 Programs COVITRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVISTIX™ (diagnostic) Antigen Test 0%* FDA Emergency COVIGUARD - SORRENTO THERAPEUTICS COVID-19 Treatment: COVIGUARD (Neutralizing Antibody – STI 1499) Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVIGUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2

infection.

CONTACT - SORRENTO THERAPEUTICS Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, CA 92121. Tel: (858) 203-4100 Fax: (858) 203-4028. info@sorrentotherapeutics.com 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 SORRENTO ANNOUNCES ADDITION OF COVI-STIX™ (COVID-19 VIRUS Sorrento Announces Addition of COVI-STIX™ (Covid-19 Virus Rapid Antigen Detection Test) to the Official Mexican Government List of Emergency Use Approved Point of Care Rapid Antigen Tests

ARK ANIMAL HEALTH

Ark Animal Health is a wholly owned subsidiary of Sorrento. Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. It is being organized to become a fully independent and self-sufficient organization once it reaches commercial stage (products ready to receive FDA approval). RTX - CANCER PAIN - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 LYMPHATIC DELIVERY SYSTEM Lymphatic Delivery System. The Sofusa ® Lymphatic Delivery System (S-LDS) is a new method of treatment designed to deliver injectable medicines directly into lymphatic and systemic capillaries just beneath the epidermis via a proprietary microneedle and microfluidics system. Sofusa Lymphatic Delivery System Overview. Visit

www.sofusa.com ».

HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 COVIGUARD - SORRENTO THERAPEUTICS COVID-19 Treatment: COVIGUARD (Neutralizing Antibody – STI 1499) Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVIGUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2

infection.

COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in

NAJJAM ASGHAR

Najjam Asghar. Mr. Asghar serves as Chief Financial Officer (CFO) leading the functions of Finance, Accounting and Tax and has over 17 years of experience. Prior to his appointment as the Company’s CFO, Mr. Asghar served as Chief Accounting Officer since June 2019. Prior to joining Sorrento, he worked at NuVasive, Inc. leading various EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 COVIGUARD - SORRENTO THERAPEUTICS COVID-19 Treatment: COVIGUARD (Neutralizing Antibody – STI 1499) Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVIGUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2

infection.

COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in

NAJJAM ASGHAR

Najjam Asghar. Mr. Asghar serves as Chief Financial Officer (CFO) leading the functions of Finance, Accounting and Tax and has over 17 years of experience. Prior to his appointment as the Company’s CFO, Mr. Asghar served as Chief Accounting Officer since June 2019. Prior to joining Sorrento, he worked at NuVasive, Inc. leading various EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on

ACEA THERAPEUTICS

ACEA Therapeutics, located in San Diego, California is a wholly owned subsidiary of Sorrento. ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. Our lead compound, Abivertinib, a small molecule kinase inhibitor, is currently under review by the China Food and Drug Administration (CFDA) for INVESTORS - SORRENTO THERAPEUTICS Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir PIPELINE - SORRENTO THERAPEUTICS Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval COVID-19 Programs COVITRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVISTIX™ (diagnostic) Antigen Test 0%* FDA Emergency MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem

ARK ANIMAL HEALTH

Ark Animal Health is a wholly owned subsidiary of Sorrento. Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. It is being organized to become a fully independent and self-sufficient organization once it reaches commercial stage (products ready to receive FDA approval). 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 RTX - KNEE ARTHRITIS - SORRENTO THERAPEUTICS RTX is our product candidate for control of pain associated with knee arthritis A Single Treatment With the Potential for Long-Lasting Results There are more than 100 million outpatient visits due to arthritis and an estimated 6.7 million hospitalizations due to arthritis An estimated 31 million adults have OA. Currently, there is

no cure. OA

RTX - CANCER PAIN - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

CAR T / DAR T

CAR T (Chimeric Antigen Receptor-T Cell) Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors. The CAR T program includes CD38, CEA and CD123. Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity. The company’s CD38 LYMPHATIC DELIVERY SYSTEM Lymphatic Delivery System. The Sofusa ® Lymphatic Delivery System (S-LDS) is a new method of treatment designed to deliver injectable medicines directly into lymphatic and systemic capillaries just beneath the epidermis via a proprietary microneedle and microfluidics system. Sofusa Lymphatic Delivery System Overview. Visit

www.sofusa.com ».

HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 COVIGUARD - SORRENTO THERAPEUTICS COVID-19 Treatment: COVIGUARD (Neutralizing Antibody – STI 1499) Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVIGUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2

infection.

COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in

NAJJAM ASGHAR

Najjam Asghar. Mr. Asghar serves as Chief Financial Officer (CFO) leading the functions of Finance, Accounting and Tax and has over 17 years of experience. Prior to his appointment as the Company’s CFO, Mr. Asghar served as Chief Accounting Officer since June 2019. Prior to joining Sorrento, he worked at NuVasive, Inc. leading various EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 COVIGUARD - SORRENTO THERAPEUTICS COVID-19 Treatment: COVIGUARD (Neutralizing Antibody – STI 1499) Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVIGUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2

infection.

COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in

NAJJAM ASGHAR

Najjam Asghar. Mr. Asghar serves as Chief Financial Officer (CFO) leading the functions of Finance, Accounting and Tax and has over 17 years of experience. Prior to his appointment as the Company’s CFO, Mr. Asghar served as Chief Accounting Officer since June 2019. Prior to joining Sorrento, he worked at NuVasive, Inc. leading various EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on

ACEA THERAPEUTICS

ACEA Therapeutics, located in San Diego, California is a wholly owned subsidiary of Sorrento. ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. Our lead compound, Abivertinib, a small molecule kinase inhibitor, is currently under review by the China Food and Drug Administration (CFDA) for INVESTORS - SORRENTO THERAPEUTICS Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir PIPELINE - SORRENTO THERAPEUTICS Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval COVID-19 Programs COVITRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVISTIX™ (diagnostic) Antigen Test 0%* FDA Emergency MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem

ARK ANIMAL HEALTH

Ark Animal Health is a wholly owned subsidiary of Sorrento. Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. It is being organized to become a fully independent and self-sufficient organization once it reaches commercial stage (products ready to receive FDA approval). 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 RTX - KNEE ARTHRITIS - SORRENTO THERAPEUTICS RTX is our product candidate for control of pain associated with knee arthritis A Single Treatment With the Potential for Long-Lasting Results There are more than 100 million outpatient visits due to arthritis and an estimated 6.7 million hospitalizations due to arthritis An estimated 31 million adults have OA. Currently, there is

no cure. OA

RTX - CANCER PAIN - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

CAR T / DAR T

CAR T (Chimeric Antigen Receptor-T Cell) Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors. The CAR T program includes CD38, CEA and CD123. Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity. The company’s CD38 LYMPHATIC DELIVERY SYSTEM Lymphatic Delivery System. The Sofusa ® Lymphatic Delivery System (S-LDS) is a new method of treatment designed to deliver injectable medicines directly into lymphatic and systemic capillaries just beneath the epidermis via a proprietary microneedle and microfluidics system. Sofusa Lymphatic Delivery System Overview. Visit

www.sofusa.com ».

HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 INVESTORS - SORRENTO THERAPEUTICSNEWS RELEASESPIPELINEPRESENTATIONSDMCACORPORATE GOVERNANCECONTACT IR Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir PIPELINE - SORRENTO THERAPEUTICS Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval COVID-19 Programs COVITRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVISTIX™ (diagnostic) Antigen Test 0%* FDA Emergency CAREERS - SORRENTO THERAPEUTICS Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes stock options, medical, dental, life and disability insurance, 401k and paid holidays.

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

CAR T / DAR T

CAR T (Chimeric Antigen Receptor-T Cell) Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors. The CAR T program includes CD38, CEA and CD123. Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity. The company’s CD38 MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 INVESTORS - SORRENTO THERAPEUTICSNEWS RELEASESPIPELINEPRESENTATIONSDMCACORPORATE GOVERNANCECONTACT IR Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir PIPELINE - SORRENTO THERAPEUTICS Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval COVID-19 Programs COVITRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVISTIX™ (diagnostic) Antigen Test 0%* FDA Emergency CAREERS - SORRENTO THERAPEUTICS Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes stock options, medical, dental, life and disability insurance, 401k and paid holidays.

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

CAR T / DAR T

CAR T (Chimeric Antigen Receptor-T Cell) Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors. The CAR T program includes CD38, CEA and CD123. Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity. The company’s CD38 MIKE ROYAL - SORRENTO THERAPEUTICS Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on

ACEA THERAPEUTICS

ACEA Therapeutics, located in San Diego, California is a wholly owned subsidiary of Sorrento. ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. Our lead compound, Abivertinib, a small molecule kinase inhibitor, is currently under review by the China Food and Drug Administration (CFDA) for INVESTORS - SORRENTO THERAPEUTICS Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir COVIGUARD - SORRENTO THERAPEUTICS COVID-19 Treatment: COVIGUARD (Neutralizing Antibody – STI 1499) Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVIGUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2

infection.

COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2 CONTACT - SORRENTO THERAPEUTICS Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, CA 92121. Tel: (858) 203-4100 Fax: (858) 203-4028. info@sorrentotherapeutics.com COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem

ARK ANIMAL HEALTH

Ark Animal Health is a wholly owned subsidiary of Sorrento. Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. It is being organized to become a fully independent and self-sufficient organization once it reaches commercial stage (products ready to receive FDA approval). TRADEMARKS - SORRENTO THERAPEUTICS Trademark Policy The tradenames, trademarks, service marks, logos, icons and trade dress of Sorrento Therapeutics, Inc. (“SORRENTO”), appearing on this website and in any of our utilities, programs and applications may not be used in any manner by users of this website, utilities, programs and applications without the express prior written permission of SORRENTO. Such RTX - CANCER PAIN - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 INVESTORS - SORRENTO THERAPEUTICSNEWS RELEASESPIPELINEPRESENTATIONSDMCACORPORATE GOVERNANCECONTACT IR Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir PIPELINE - SORRENTO THERAPEUTICS Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval COVID-19 Programs COVITRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVISTIX™ (diagnostic) Antigen Test 0%* FDA Emergency CAREERS - SORRENTO THERAPEUTICS Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes stock options, medical, dental, life and disability insurance, 401k and paid holidays.

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

CAR T / DAR T

CAR T (Chimeric Antigen Receptor-T Cell) Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors. The CAR T program includes CD38, CEA and CD123. Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity. The company’s CD38 MIKE ROYAL - SORRENTO THERAPEUTICSMIKE ROYAL MDMIKE ROYAL SUMMERVILLE SCLATEST NEWS ON SORRENTO THERAPEUTICSMIKE RITCHIE FACEBOOKSORRENTO THERAPEUTICS COMPANYSORRENTO THERAPEUTICS WIKIPEDIA Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on HOME - SORRENTO THERAPEUTICSWHO WE ARERESEARCHMANUFACTURINGSUBSIDIARIESPARTNERSHIPINVESTORS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19 INVESTORS - SORRENTO THERAPEUTICSNEWS RELEASESPIPELINEPRESENTATIONSDMCACORPORATE GOVERNANCECONTACT IR Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir PIPELINE - SORRENTO THERAPEUTICS Sorrento’s R&D is focused on driving innovation in COVID-19, cancer treatment, full pain control and autoimmune diseases Portfolio Key Programs Indication Preclinical Phase I Phase II Phase III/Pivotal FDA Approval COVID-19 Programs COVITRACE™ (diagnostic) Diagnostic Test 0%* FDA Emergency Use Authorization (EUA) Application Expected COVISTIX™ (diagnostic) Antigen Test 0%* FDA Emergency CAREERS - SORRENTO THERAPEUTICS Sorrento Therapeutics, Inc. is an Equal Opportunity Employer and offers candidates an attractive salary and comprehensive benefits package that includes stock options, medical, dental, life and disability insurance, 401k and paid holidays.

ABIVERTINIB

ABIVERTINIB (Cytokine Storm – STI 5656) Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK). On May 21, 2020, Sorrento announced that it had entered into a binding term sheet for an exclusive license to ACEA Therapeutics’ 10Q - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

CAR T / DAR T

CAR T (Chimeric Antigen Receptor-T Cell) Sorrento’s cellular therapy programs focus on Chimeric Antigen Receptor-T Cell (CAR T) for adoptive cellular immunotherapy to treat both solid and liquid tumors. The CAR T program includes CD38, CEA and CD123. Sorrento’s CD38 CAR T targets high-expressing CD38 positive cells, which may limit on-target/off-tumor toxicity. The company’s CD38 MIKE ROYAL - SORRENTO THERAPEUTICSMIKE ROYAL MDMIKE ROYAL SUMMERVILLE SCLATEST NEWS ON SORRENTO THERAPEUTICSMIKE RITCHIE FACEBOOKSORRENTO THERAPEUTICS COMPANYSORRENTO THERAPEUTICS WIKIPEDIA Dr. Royal is a pharmaceutical executive with 20 years of clinical development and medical affairs. Recently, he was the Chief Medical Officer of Suzhou Connect Biopharmaceuticals and, prior to that, Concentric Analgesics. He rejoins Sorrento where he was previously EVP, Clinical Development and Regulatory Affairs in 2016 He has been responsible for or instrumental in EDGAR LEE - BOARD MEMBER - SORRENTO THERAPEUTICS Edgar Lee. Director. Mr. Lee founded and was the portfolio manager of Oaktree Capital Management’s $5.5bn Strategic Credit strategy. He was also the CEO and Chief Investment Officer of Oaktree’s three business development companies (BDCs) including Oaktree Specialty Lending and Oaktree Strategic Income Corporations. Previously, he was

an

DORMAN FOLLOWWILL

Dorman Followwill, age 54, has been Senior Partner, Transformational Health at Frost & Sullivan, a business consulting firm involved in market research and analysis, growth strategy consulting and corporate training across multiple industries, since 2016. Prior to that time, he served in various roles at Frost & Sullivan, including Partner on

ACEA THERAPEUTICS

ACEA Therapeutics, located in San Diego, California is a wholly owned subsidiary of Sorrento. ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. Our lead compound, Abivertinib, a small molecule kinase inhibitor, is currently under review by the China Food and Drug Administration (CFDA) for INVESTORS - SORRENTO THERAPEUTICS Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new treatments for COVID-19, cancer, and pain. Sorrento's extensive immunotherapy platforms include proprietary assets such as fully human antibodies (G-MAB™ library), clinical stage cellular therapies (CAR-T, DAR-T™), antibody-drug conjugates (ADCs), clinical stage oncolytic viruses (Seprehvir COVIGUARD - SORRENTO THERAPEUTICS COVID-19 Treatment: COVIGUARD (Neutralizing Antibody – STI 1499) Sorrento is developing a Neutralizing Antibody which binds to S1 subunit of SARS-CoV-2 Spike protein. COVIGUARD Fc region is engineered to eliminate interactions with host Fc receptors, thereby potentially decreasing risk of Antibody Dependent Enhancement of SARS-CoV-2

infection.

COVI-AMG - SORRENTO THERAPEUTICS COVI-AMG (Affinity Matured COVI-GUARD Neutralizing Antibody – STI 2020) Sorrento is developing COVI-AMG™ (STI-2020; Affinity Matured COVI-Guard) neutralizing antibodies (nAbs) against SARS-CoV-2 infection. STI-2020 has demonstrated greater than 50-fold increase in potency in in vitro experiments. In preclinical cell-based assay, STI-2020 has shown 100% in vitro neutralization of SARS-CoV-2 CONTACT - SORRENTO THERAPEUTICS Sorrento Therapeutics, Inc. 4955 Directors Place San Diego, CA 92121. Tel: (858) 203-4100 Fax: (858) 203-4028. info@sorrentotherapeutics.com COVITRACK - SORRENTO THERAPEUTICS Sorrento is developing the COVITRACK TM in vitro diagnostic test kit for the detection of IgG and IgM antibodies in blood samples from patients who may have been exposed to the SARS-CoV-2 virus.. The rapid antibody test kit is easy to use and allows for results to be available in about eight minutes. The test develops two clear lines on independent tracks confirm the detection and MESENCHYMAL STEM CELL COVI-MSC (Acute Respiratory Distress Syndrome – STI 8282) Sorrento is entering Phase I Trial of COVI-MSC for patients suffering from Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19, which have been cleared by the FDA. The primary objective of the Phase 1 study is to evaluate the safety of intravenous infusion of allogeneic adipose stem

ARK ANIMAL HEALTH

Ark Animal Health is a wholly owned subsidiary of Sorrento. Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. It is being organized to become a fully independent and self-sufficient organization once it reaches commercial stage (products ready to receive FDA approval). TRADEMARKS - SORRENTO THERAPEUTICS Trademark Policy The tradenames, trademarks, service marks, logos, icons and trade dress of Sorrento Therapeutics, Inc. (“SORRENTO”), appearing on this website and in any of our utilities, programs and applications may not be used in any manner by users of this website, utilities, programs and applications without the express prior written permission of SORRENTO. Such RTX - CANCER PAIN - SORRENTO THERAPEUTICS Sorrento Therapeutics - We apply cutting-edge science to create innovative therapies that will improve the lives of those who suffer from cancer, intractable pain and COVID-19

* Careers

* Contact

MENU

Skip to content

* Company

* Our Vision & Mission

* Our People

* Our Leadership

* Board of Directors

* Manufacturing

* Affiliations

* Investors

* News & Events

* Events Calendar

* Presentations

* Financials

* Fundamentals

* Stock

* Historical Price Lookup * Investment Calculator

* Ownership Summary

* Estimates

* Governance

* Board of Directors * Committee Composition * Shareholder Services

* Email Alerts

* Pipeline

* Platforms

* Immuno-Oncology Assets

* G-MABs™

* CAR-T

* ADCs

* iTAbs

* Oncolytic Virus

* Pain Management Assets

* ZTlido™

* RTX

* Translational Efficiencies

Immuno-Oncology

* G-MABS™

* CAR-T

* ADCs

* iTAbs

* Oncolytic Virus

TURNING MALIGNANT CANCERS INTO MANAGEABLE, AND POSSIBLY CURABLE,

CHRONIC DISEASES.

Non-Opioids

for Pain

* ZTlido™

* Resiniferatoxin (RTX) NOVEL THERAPIES TO EASE PATIENTS’ DISEASE OR TREATMENT RELATED

SUFFERING.

* G-MABs™

* CAR-T

* ADCs

* iTAbs

* Oncolytic Virus

* ZTlido™

* Resiniferatoxin (RTX) TURNING MALIGNANT CANCERS INTO MANAGEABLE, AND POSSIBLY CURABLE,

CHRONIC DISEASES.

NOVEL THERAPIES TO EASE PATIENTS’ DISEASE OR TREATMENT RELATED

SUFFERING.

CLINICAL TRIALS

clinicaltrials@sorrentotherapeutics.com INVESTORS investors@sorrentotherapeutics.com BUSINESS DEVELOPMENT business@sorrentotherapeutics.com MEDIA REQUESTS mediarelations@sorrentotherapeutics.com � 2020 Sorrento Therapeutics, Inc. All Rights Reserved.

* Terms of Use

* Privacy Policy

* DMCA

* Trademarks

* Linking Policy

* Notices

* LinkedIn

MENU

* Company

* Our Vision & Mission

* Our People

* Our Leadership

* Board of Directors

* Manufacturing

* Affiliations

* Investors

* News & Events

* Events Calendar

* Presentations

* Financials

* Fundamentals

* Stock

* Historical Price Lookup * Investment Calculator

* Ownership Summary

* Estimates

* Governance

* Board of Directors * Committee Composition * Shareholder Services

* Email Alerts

* Pipeline

* Platforms

* Immuno-Oncology Assets

* G-MABs™

* CAR-T

* Antibody Drug Conjugates (ADCs)

* iTAbs

* Oncolytic Virus

* Pain Management Assets

* RTX

* ZTlido™

* Translational Efficiencies

* Careers

* Contact